Discovery Partners International, Inc., have announced that they have entered into a new drug discovery collaboration with Mitsubishi Pharma Corporation (Mitsubishi) to discover lead compounds for a therapeutic target selected by Mitsubishi.
DPI will make use of its comprehensive drug-like compound collection and leverage its expertise in assay development, high-throughput screening, and computational chemistry.
"We have had a successful history collaborating with Mitsubishi, and we are very pleased that Mitsubishi has decided to continue collaborating with Discovery Partners in a new target area," stated Riccardo Pigliucci, Chairman and CEO of Discovery Partners.
"This discovery collaboration serves as a strong testimony to our commitment to building long-term and value-added relationships with our pharmaceutical partners. The integrated drug discovery platform at DPI is enabled from target to optimized leads. Our collaboration model complements the needs of our partners to support any or all phases of the drug discovery process."